B7-H3 UCAR-T cells

B7-H3 UCAR-T cells are genetically engineered allogeneic (universal) chimeric antigen receptor (CAR) T cell therapies designed to target the tumor-associated antigen B7-H3 (CD276), which is highly expressed on a wide range of solid tumors and some hematologic malignancies. The therapy involves modifying donor-derived or universal T lymphocytes to express a synthetic receptor that recognizes and binds to the B7-H3 protein on cancer cell surfaces. Upon binding, these modified T-cells become activated and mediate direct cytotoxicity against tumor cells expressing high levels of B7-H3. Preclinical studies have demonstrated significant antitumor activity in models of pediatric solid tumors such as osteosarcoma, medulloblastoma, Ewing sarcoma, glioblastoma, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), prostate cancer, intrahepatic cholangiocarcinoma (ICC), pancreatic ductal adenocarcinoma (PDAC), and chordoma[1][2][4]. Early-phase clinical trials indicate that autologous versions are safe with manageable toxicity profiles in children and young adults with relapsed or refractory solid tumors[5][6]. The universal/allogeneic approach aims to provide an off-the-shelf product for broader patient access.

Other names

B7-H3 CAR T cellsB-7-H3 CAR T cellsB 7-H3 CAR T cellsB7H3 CAR T cellsB-7H3 CAR T cellsB 7H3 CAR T cellsCD276 CAR T cellsCD-276 CAR T cellsCD 276 CAR T cellsB7-H3 chimeric antigen receptor T cellsB-7-H3 chimeric antigen receptor T cellsB 7-H3 chimeric antigen receptor T cells